Dominant-negative HMGA1 blocks mu enhancer activation through a novel mechanism

Biochemical and Biophysical Research Communications
A AndreucciB S Nikolajczyk

Abstract

The immunoglobulin mu intronic enhancer is a potent B cell-specific transcriptional activator. The enhancer is activated by the appropriate combination of transcription factors, amongst which are ets and bHLH proteins. HMGA1 (formerly HMG-I(Y)) is a demonstrated co-activator of the mu enhancer. HMGA1 functions through direct interaction with PU.1, one of the ets proteins critical for enhancer activation. New data demonstrates dominant negative HMGA1 dramatically decreases enhancer activity in B cells. EMSA analysis demonstrated that DN HMGA1 disrupts established PU.1/mu enhancer binding. Similarly, DN HMGA1 blocks mu enhancer binding by Ets-1. In sharp contrast, DN HMGA1 had no effect on binding activity of the ETS DNA binding domains of either PU.1 or Ets-1, or the bHLH-zip protein TFE3, suggesting specificity. Taken together, the data suggest that DN HMGA1 utilizes a novel mechanism to specifically block interaction between ets proteins and mu enhancer DNA, suggesting DN HMGA1 represents a new, highly specific means of regulating mu enhancer activity.

References

Aug 1, 1996·Molecular and Cellular Biology·B S NikolajczykR Sen
Jun 1, 1997·Molecular and Cellular Biology·K MerrellK Calame
Jul 1, 1997·Molecular and Cellular Biology·B S NikolajczykR Sen
Oct 17, 1998·Molecular and Cellular Biology·W DangR Sen
Jul 10, 1999·The Journal of Biological Chemistry·X M Zhang, G L Verdine
Mar 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S R HimesM F Shannon
Jan 1, 2001·The Journal of Biological Chemistry·R T LewisB S Nikolajczyk

❮ Previous
Next ❯

Citations

Aug 9, 2003·The Journal of Biological Chemistry·Kevin M McCarthyBarbara S Nikolajczyk

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.